Chemoprevention of severe neonatal hyperbilirubinemia.


The uses of synthetic heme analogues that are competitive inhibitors of heme oxygenase, the rate-limiting enzyme in the production of bilirubin, represent a novel means of controlling severe hyperbilirubinemia in the newborn. The logic of this approach and the use of stannsoporfin (tin mesoporphyrin) as the compound of choice are discussed. 


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics